GlassScriptPhysician profile
Nidal M Boutros
NPI 1629036173
$4,880.45
in general payments reported to CMS, 2019-2025
42 companies · $554 in 2025
The $554 reported for 2025 was more than what 75% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $492 · 2020: $261 · 2021: $997 · 2022: $864 · 2023: $1,148 · 2024: $565 · 2025: $554.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,267.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,266.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,036.03 | 2019-2025 | Ubrelvy, Vraylar, Qulipta |
| Pfizer INC. | $572.26 | 2019-2025 | |
| Novo Nordisk INC | $507.65 | 2019-2025 | Ozempic, Rybelsus, Sogroya |
| Lilly USA, LLC | $290.26 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Astrazeneca Pharmaceuticals LP | $285.83 | 2019-2025 | Breztri, Airsupra, Farxiga |
| Amgen INC. | $278.55 | 2019-2025 | Evenity, Prolia, Otezla |
| Eisai INC. | $222.13 | 2020-2022 | |
| Sanofi-Aventis U.S. LLC | $170.14 | 2021-2023 | |
| Amarin Pharma, INC. | $126.33 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $122.20 | 2019-2025 | Jardiance |
| Merck Sharp & Dohme LLC | $118.26 | 2021-2023 | Belsomra, Steglatro |
| Janssen Pharmaceuticals, INC | $106.11 | 2021-2023 | Xarelto |
| Glaxosmithkline, LLC. | $87.97 | 2019-2024 | Trelegy Ellipta, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $86.37 | 2021-2023 | |
| Ultragenyx Pharmaceutical INC. | $65.92 | 2020-2022 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nidal Boutros listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.